Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iniparib + pegylated liposomal doxorubicin + carboplatin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a **three-drug combination regimen** consisting of **iniparib** (formerly thought to be a PARP inhibitor, now recognized to have cytotoxic effects via an undefined mechanism), **pegylated liposomal doxorubicin** (a liposome-encapsulated formulation of the anthracycline doxorubicin, which intercalates DNA and inhibits topoisomerase II), and **carboplatin** (a platinum-based DNA-damaging chemotherapeutic agent). This combination was evaluated in clinical trials for the treatment of ovarian cancer, in particular for platinum-resistant or recurrent settings. While iniparib was originally believed to act as a PARP inhibitor, subsequent evidence indicates its mechanism is distinct and not canonical PARP inhibition. **Pegylated liposomal doxorubicin** is designed for improved pharmacokinetics and reduced cardiotoxicity compared to conventional doxorubicin. **Carboplatin** induces DNA cross-links, leading to apoptosis.
- Brand names
- None known for this specific combination
- Other names
- None known for this specific combination
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on iniparib + pegylated liposomal doxorubicin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iniparib + pegylated liposomal doxorubicin + carboplatin.